Navigation Links
Next-generation allergy vaccines to be developed in Finland to create effective and safe desensitization therapies
Date:10/21/2011

VTT holds patents on gene technology which can be applied to alter the structure of an allergen, i.e. a protein causing allergy, so that it will cause less allergic symptoms than the original allergen, while remaining effective in desensitisation therapy.

"The vaccine helps to improve the protection to the allergen, thus, alleviating the symptoms. That's why we prefer to use the term vaccine, instead of medication," VTT's Senior Advisor Hans Sderlund explains. The research objective is to develop an orally administered vaccine.

The foundation for this development rests on a scientific breakthrough dating back five years to a co-operation project involving VTT, the University of Eastern Finland and HUCH Skin and Allergy Hospital. Researchers were able to determine how an IgE antibody binds an allergen and were the first to present a detailed 3D structure of this complex. This proved to be different from what scientists around the world had anticipated.

Initially, Desentum Oy will develop a product line of 20 to 25 new hypoallergens which could be used as vaccines for some of the most important allergies. These include pollens (birch, hay, common wormwood, etc.), allergens from pets, and proteins associated with food allergies (fish, nuts, apple, celery). Clinical testing of the first products is anticipated to start within the next three years.

Pekka Mattila, Desentum Oy's Managing Director, knows how to run a biotechnology company and increase its business opportunities. He was one of the founding members of the Finnzymes Group and acted as its CEO until 2010, when the company was sold to the American Thermo Fisher Scientific.

What is an allergy?

Allergies are caused by the immune reaction to normally harmless proteins allergens - present in environment, food or consumer and medical products. Due to sensitisation, the body generates Immunoglobulin E (IgE) antibodies. Next time when these antibodies recognise the same allergen, they trigger an allergic reaction and cause symptoms in the respiratory or digestive system, or the skin. An extreme allergic reaction may cause anaphylaxis or even death.

The prevalence of allergies and allergic reactions has increased in the industrialised countries, and they are now estimated to belong to the top five most costly disease groups. In Europe, the number of people suffering from allergies is estimated to exceed 80 million, while in the US the corresponding number is 65 million. According to further estimates, half of the European population will suffer from an allergy by 2015.

In the US alone, the market for antiallergic drugs is anticipated to exceed USD 15 billion by 2015. In 2010, the estimated market for new allergy vaccines is approximately USD 700 million.


'/>"/>

Contact: Hans Soderlund Professor
Hans.soderlund@vtt.fi
358-207-225-104
VTT Technical Research Centre of Finland
Source:Eurekalert

Related medicine news :

1. In search of cancers common ground: A next-generation view
2. Next-generation hospital design can improve health -- and save money
3. Proteins in unroasted coffee beans may become next-generation insecticides
4. Viscira™ Earns Industry Praise for Next-Generation 3D Animation Production
5. Pharmacokinetic/Pharmacodynamic Data Support Further Development of Tobiras Next-Generation CCR5 Receptor Antagonist
6. Black Children May Be More Prone to Peanut Allergy, Study Finds
7. Switch to Powder-Free Latex Gloves Cuts Health Workers Allergy Risk
8. Longer Allergy Season Means More Misery
9. Using powder-free latex gloves reduces latex allergy rate in health care workers
10. Nut-allergy sufferers face prejudice -- new study
11. Prenatal pet exposure, delivery mode, race are key factors in early allergy risk
Post Your Comments:
*Name:
*Comment:
*Email:
(Date:5/27/2016)... (PRWEB) , ... May 27, 2016 , ... ... readers, this installment is bolstered by inspiring human-interest stories, courtesy of awareness-driven celebrities ... within the industry, from leading advocates, associations and industry leaders such as Bioness. ...
(Date:5/27/2016)... ... 2016 , ... Each year Standard Process Inc. ... this year’s Life University winner of a $2,500 scholarship from Standard ... Awards ceremony. , Outerbridge is approaching her last quarter at Life University in ...
(Date:5/26/2016)... ... May 26, 2016 , ... Cabot Corporation, Pfizer, and 3M ... to court documents and SEC filings. A jury has returned a verdict ... Optical Corporation, Case No. BC588866, Los Angeles County, California. The jury awarded $22.8 ...
(Date:5/26/2016)... ... 2016 , ... The Woodlands at John Knox Village , Florida’s first ... for living and healing, celebrated its grand opening, today. The Woodlands at John Knox ... by Empowered Staff. , “This is an incredibly fulfilling time for John Knox Village ...
(Date:5/26/2016)... (PRWEB) , ... May 26, 2016 , ... ... Retinal Degeneration” for the Foundation Fighting Blindness, Long Island Chapter on June 4, ... the public. , Dr. Maisel, founder of Retina Group of New York ...
Breaking Medicine News(10 mins):
(Date:5/25/2016)... 25, 2016  Granger Diagnostics today announced immediate availability ... and infections. This test ensures discovery of ALL ... The test requires only a simple swab of the ... David G. Bostwick , MD, Chief Medical Officer, ... healing: "We are excited to make available, for ...
(Date:5/25/2016)... , May 25, 2016 ... the precision of circulating tumour DNA (ctDNA) analysis ... the appointment of Professor Clive Morris ... leadership across the clinical development programme, scientific collaborations, ... help deliver significant improvements in clinical outcomes for ...
(Date:5/24/2016)... 2016 Cirujanos holandeses han puesto ... los médicos a compartir sus mejores prácticas por el ... Profesionales médicos de Europa, África, Asia ... la aplicación, que combina la transmisión en vivo con ... Educación   "Imagine un médico de ...
Breaking Medicine Technology: